BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 16624621)

  • 61. Gene therapy. What to do when clear success comes with an unclear risk?
    Marshall E
    Science; 2002 Oct; 298(5593):510-1. PubMed ID: 12386304
    [No Abstract]   [Full Text] [Related]  

  • 62. Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice.
    Westwood JA; Murray WK; Trivett M; Shin A; Neeson P; MacGregor DP; Haynes NM; Trapani JA; Mayura-Guru P; Fox S; Peinert S; Honemann D; Prince HM; Ritchie D; Scott AM; Smyth FE; Smyth MJ; Darcy PK; Kershaw MH
    Gene Ther; 2008 Jul; 15(14):1056-66. PubMed ID: 18369322
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cellular gene therapy.
    Lee JH; Klein HG
    Hematol Oncol Clin North Am; 1995 Feb; 9(1):91-113. PubMed ID: 7737946
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Transcription start regions in the human genome are favored targets for MLV integration.
    Wu X; Li Y; Crise B; Burgess SM
    Science; 2003 Jun; 300(5626):1749-51. PubMed ID: 12805549
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Gene therapy. Panel urges limits on X-SCID trials.
    Kaiser J
    Science; 2005 Mar; 307(5715):1544-5. PubMed ID: 15761128
    [No Abstract]   [Full Text] [Related]  

  • 66. Physiological promoters reduce the genotoxic risk of integrating gene vectors.
    Zychlinski D; Schambach A; Modlich U; Maetzig T; Meyer J; Grassman E; Mishra A; Baum C
    Mol Ther; 2008 Apr; 16(4):718-25. PubMed ID: 18334985
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors.
    Schucht R; Coroadinha AS; Zanta-Boussif MA; Verhoeyen E; Carrondo MJ; Hauser H; Wirth D
    Mol Ther; 2006 Aug; 14(2):285-92. PubMed ID: 16697259
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bubble babies and bathwater.
    Nat Biotechnol; 2002 Nov; 20(11):1063. PubMed ID: 12410236
    [No Abstract]   [Full Text] [Related]  

  • 69. Genome-wide analysis of retroviral DNA integration.
    Bushman F; Lewinski M; Ciuffi A; Barr S; Leipzig J; Hannenhalli S; Hoffmann C
    Nat Rev Microbiol; 2005 Nov; 3(11):848-58. PubMed ID: 16175173
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical research. Gene therapy a suspect in leukemia-like disease.
    Marshall E
    Science; 2002 Oct; 298(5591):34-5. PubMed ID: 12364755
    [No Abstract]   [Full Text] [Related]  

  • 71. The US and EU regulatory perspectives on the clinical use of hematopoietic stem/progenitor cells genetically modified ex vivo by retroviral vectors.
    Wilson CA; Cichutek K
    Methods Mol Biol; 2009; 506():477-88. PubMed ID: 19110646
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy.
    Uchibori R; Okada T; Ito T; Urabe M; Mizukami H; Kume A; Ozawa K
    J Gene Med; 2009 May; 11(5):373-81. PubMed ID: 19274675
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Gene therapy: therapeutic gene causing lymphoma.
    Woods NB; Bottero V; Schmidt M; von Kalle C; Verma IM
    Nature; 2006 Apr; 440(7088):1123. PubMed ID: 16641981
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Retroviral DNA integration.
    Coffin JM
    Dev Biol Stand; 1992; 76():141-51. PubMed ID: 1478335
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Murine leukemia induced by retroviral gene marking.
    Li Z; Düllmann J; Schiedlmeier B; Schmidt M; von Kalle C; Meyer J; Forster M; Stocking C; Wahlers A; Frank O; Ostertag W; Kühlcke K; Eckert HG; Fehse B; Baum C
    Science; 2002 Apr; 296(5567):497. PubMed ID: 11964471
    [No Abstract]   [Full Text] [Related]  

  • 76. Gene transfer to somatic tissues using retroviral vectors.
    Moullier P; Marechal V; Ferry N; Naffakh N; Heard JM; Danos O
    Nouv Rev Fr Hematol (1978); 1991; 33(6):493-5. PubMed ID: 1818305
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Harmful potential of viral vectors fuels doubts over gene therapy.
    Check E
    Nature; 2003 Jun; 423(6940):573-4. PubMed ID: 12789298
    [No Abstract]   [Full Text] [Related]  

  • 78. Integration site selection by retroviruses.
    Cereseto A; Giacca M
    AIDS Rev; 2004; 6(1):13-21. PubMed ID: 15168737
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Concise review: managing genotoxicity in the therapeutic modification of stem cells.
    Baum C; Modlich U; Göhring G; Schlegelberger B
    Stem Cells; 2011 Oct; 29(10):1479-84. PubMed ID: 21898683
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Gene therapy bio-safety: scientific and regulatory issues.
    Gonin P; Buchholz CJ; Pallardy M; Mezzina M
    Gene Ther; 2005 Oct; 12 Suppl 1():S146-52. PubMed ID: 16231047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.